Ann Lab Med.  2017 Sep;37(5):450-453. 10.3343/alm.2017.37.5.450.

Correlation Between Bone Marrow Blasts Counts With Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes

• Huang M
• Zhao X
• Xu H
• Liu S
• Wang Z
• Sui X
• Li J

• KMID: 2383924
• DOI: http://doi.org/10.3343/alm.2017.37.5.450

Abstract

No abstract available.

MeSH Terms

Bone Marrow*
Flow Cytometry*
Myelodysplastic Syndromes*

Figure

• 

  Fig. 1 Degree of agreement between bone marrow blast counts by flow cytometry and conventional morphology in MDS. The abscissae represent the mean percentage of bone marrow blasts obtained by morphology and flow cytometry for each patient, and the ordinates represent the difference in the percentages of bone marrow blasts obtained by morphology and flow cytometry for each patient. Panels A, B, and C show flow cytometry counts obtained with strategies A1, A2, and A3, respectively, and panels D, E, and F show flow cytometry blast percentages with the N1, N2, and N3 strategies, respectively. Panels G, H, and I show flow cytometry counts obtained with strategies CA1, CA2, and CA3, respectively, and panels J, K, and L show the CN1, CN2, and CN3 strategies, respectively. The percentages in the Bland-Altman plots indicate the number of cases within the 95% limits of agreement.

Reference

1. Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 2011; 38:627–634. PMID: 21943669.

2. van de Loosdrecht AA, Westers TM. Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw. 2013; 11:892–902. PMID: 23847222.

3. Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014; 28:1793–1798. PMID: 24919805.

4. van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004; 60:1–13. PMID: 15221864.

5. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001; 98:979–987. PMID: 11493442.

6. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol. 2006; 125:884–894. PMID: 16690488.

7. Bellos F, Kern W. Flow cytometry in the diagnosis of myelodysplastic syndromes and the value of myeloid nuclear differentiation antigen. Cytometry B Clin Cytom. 2017; 92:200–206. PMID: 26184452.

8. Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores J, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008; 22:1175–1183. PMID: 18337765.

9. Orfao A, Ortuño F, de Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A. 2004; 58:62–71. PMID: 14994223.

10. Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010; 78:154–168. PMID: 20198685.